May 8th 2024
The industry must find a way to balance consumer privacy and a return on investment in pharma marketing.
FDA Approves Microbiome Therapeutic Vowst to Prevent Recurrence of C. difficile Infections in Adults
May 1st 2023Seres Therapeutics and Nestlé Health Science celebrate the FDA's approval of Vowst, a first-of-its-kind orally administered microbiota-based therapeutic set to transform the lives of patients with recurrent C. difficile infections.